A092040 Stock Overview
Operates as an industrial biotechnology company in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Amicogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,350.00 |
| 52 Week High | ₩9,490.00 |
| 52 Week Low | ₩4,755.00 |
| Beta | 1.09 |
| 11 Month Change | -23.24% |
| 3 Month Change | -34.11% |
| 1 Year Change | -42.07% |
| 33 Year Change | -73.87% |
| 5 Year Change | -55.69% |
| Change since IPO | -25.57% |
Recent News & Updates
Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding
Jun 27
Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?
Jun 19Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%
Mar 21Recent updates
Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding
Jun 27Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?
Jun 19Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%
Mar 21With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting
Mar 23Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?
Mar 05Is Amicogen (KOSDAQ:092040) A Risky Investment?
Feb 15
What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?
Jan 31Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?
Jan 14Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?
Dec 30Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?
Dec 15Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?
Nov 30Shareholder Returns
| A092040 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.5% | 0.7% | 1.3% |
| 1Y | -42.1% | 21.8% | 8.4% |
Return vs Industry: A092040 underperformed the KR Biotechs industry which returned 21.8% over the past year.
Return vs Market: A092040 underperformed the KR Market which returned 8.4% over the past year.
Price Volatility
| A092040 volatility | |
|---|---|
| A092040 Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.0% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A092040's share price has been volatile over the past 3 months.
Volatility Over Time: A092040's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 216 | n/a | www.amicogen.com |
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. It also offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, and feed sectors.
Amicogen, Inc. Fundamentals Summary
| A092040 fundamental statistics | |
|---|---|
| Market cap | ₩293.27b |
| Earnings (TTM) | -₩30.71b |
| Revenue (TTM) | ₩155.88b |
1.9x
P/S Ratio-9.5x
P/E RatioIs A092040 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A092040 income statement (TTM) | |
|---|---|
| Revenue | ₩155.88b |
| Cost of Revenue | ₩103.57b |
| Gross Profit | ₩52.31b |
| Other Expenses | ₩83.02b |
| Earnings | -₩30.71b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -560.21 |
| Gross Margin | 33.56% |
| Net Profit Margin | -19.70% |
| Debt/Equity Ratio | 80.5% |
How did A092040 perform over the long term?
See historical performance and comparison